DNA repair pathways and non-small cell lung cancer: Clinical perspectives;Voies de réparation de l'ADN et cancers bronchiques non à petites cellules: Perspectives cliniques

Bulletin du Cancer

Volumn 98, Issue 3, 2011, Pages 305-322

  Olaussen, Ken André ^a   Planchard, David ^a   Adam, Julien ^a   Soria, Jean Charles ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Biomarkers; BRCA1 BRCA2; DNA repair; DNA repair pathway deficiency; ERCC1; Lung cancer; MSH2; NSCLC; PARP; PARP1

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; INTERMEDIN;

CELL DAMAGE; CELL DEATH; DNA REPAIR; EXCISION REPAIR; GENE MUTATION; GENETIC STABILITY; GENETIC SUSCEPTIBILITY; HOMOLOGOUS RECOMBINATION; HUMAN; LUNG NON SMALL CELL CANCER; REVIEW; TREATMENT RESPONSE;

EID: 79955083742     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1327     Document Type: Review

References (48)

1. Rixe O. Platinum salts: cytotoxic mechanisms of action, mechanisms of resistance of cancer cells, interactions with ionizing radiation, specificity of carboplatin. Bull Cancer 2000 ; Spec no : 7-15.
2. Kamal NS, Soria JC, Mendiboure J, et al. MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin Cancer Res 2010 ; 16 : 1206-15.
3. Guggenheim ER, Xu D, Zhang CX, Chang PV, Lippard SJ. Photoaffinity isolation and identification of proteins in cancer cell extracts that bind to platinum-modified DNA. Chembiochem 2009 ; 10 : 141-57.
4. Rosell R, Taron M, Ariza A, et al. Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol 2004 ; 31(Suppl. 1) : 20-7. (Pubitemid 38241017)
5. Molinete M, Vermeulen W, Buerkle A, et al. Overproduction of the poly(ADP-ribose) polymerase DNA-binding domain blocks alkylation-induced DNA repair synthesis in mammalian cells. EMBO J 1999 ; 12 : 2109-17.
6. Sarasin A. DNA lesions: mechanisms of recognition and repair. Bull Cancer 1997 ; 84 : 467-72. (Pubitemid 27211698)
7. Volker M, Moné MJ, Karmakar P, et al. Sequential assembly of the nucleotide excision repair factors in vivo. Mol Cell 2001 ; 8 : 213-24. (Pubitemid 32772919)
8. Ogi T, Limsirichaikul S, Overmeer RM, et al. Three DNA polymerases, recruited by different mechanisms, carry out NER repair synthesis in human cells. Mol Cell 2010 ; 37 : 714-27.
9. Soussi T. Record no. 23: hMLH1. Bull Cancer 1999 ; 86 : 245-6.
10. Olschwang S, Bonaïti C, Feingold J, et al. Identification and management of HNPCC syndrome (hereditary non polyposis colon cancer), hereditary predisposition to colorectal and endometrial adenocarcinomas. Bull Cancer 2004 ; 91 : 303-15. (Pubitemid 38662059)
11. Soussi T. Genes and cancer. NBS1 (Nijmegen breakage syndrome). Repair gene. Bull Cancer 1999 ; 86 : 803-4.
12. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001 ; 411 : 366-74. (Pubitemid 32467046)
13. Jackson D, Dhar K, Wahl JK, Wold MS, Borgstahl GE. Analysis of the human replication protein A:Rad52 complex: evidence for crosstalk between RPA32, RPA70, Rad52 and DNA. J Mol Biol 2002 ; 321 : 133-48. (Pubitemid 34948475)
14. Muller C, Rodrigo G, Calsou P, Salles B. DNA-dependent protein kinase: a major protein involved in the cellular response to ionizing radiation. Bull Cancer 1999 ; 86 : 977-83. (Pubitemid 30055678)
15. Motycka TA, Bessho T, Post SM, Sung P, Tomkinson AE. Physical and functional interaction between the XPF/ERCC1 endonuclease and hRad52. J Biol Chem 2004 ; 279 : 13634-9. (Pubitemid 38468890)
16. Zhang N, Liu X, Li L, Legerski R. Double-strand breaks induce homologous recombinational repair of interstrand cross-links via cooperation of MSH2, ERCC1-XPF, REV3, and the Fanconi anemia pathway. DNA Repair (Amst) 2007 ; 6 : 1670-8. (Pubitemid 47600111)
17. Niedernhofer LJ, Odijk H, Budzowska M, et al. The structurespecific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 2004 ; 24 : 5776-87. (Pubitemid 38787963)
18. Sun Y, Li T, Ma K, et al. The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells. Cancer Invest 2009 ; 27 : 891-7.
19. Puisieux A. HNPCC syndrome, microsatellite instability and NF1 gene alteration. Bull Cancer 1999 ; 86 : 812-4.
20. Al-Minawi AZ, Lee YF, Håkansson D, et al. The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links. Nucleic Acids Res 2009 ; 37 : 6400-13.
21. Al-Minawi AZ, Saleh-Gohari N, Helleday T. The ERCC1/XPF endonuclease is required for efficient single-strand annealing and gene conversion in mammalian cells. Nucleic Acids Res 2008 ; 36 : 1-9.
22. Loetscher P, Alvarez-Gonzalez R, Althaus FR. Poly(ADP-ribose) may signal changing metabolic conditions to the chromatin of mammalian cells. Proc Natl Acad Sci U S A 1987 ; 84 : 1286-9. (Pubitemid 17027338)
23. Schreiber V, Amé JC, Dollé P, et al. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 2002 ; 277 : 23028-36. (Pubitemid 34967289)
24. Larsen CJ. The BRCA2 gene protein, whose disorders predispose to familial cancer of the breast, intervene in DNA repair. Bull Cancer 1998 ; 85 : 295-6.
25. Reguart N, Cardona AF, Carrasco E, Gomez P, Taron M, Rosell R. BRCA1: a new genomic marker for non-small-cell lung cancer. Clin Lung Cancer 2008 ; 9 : 331-9.
26. Barreto G, Schäfer A, Marhold J, et al. Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature 2007 ; 445 : 671-5. (Pubitemid 46232889)
27. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009 ; 461 : 1071-8.
28. Hamelin R, Chalastanis A, Colas C, et al. Clinical and molecular consequences of microsatellite instability in human cancers. Bull Cancer 2008 ; 95 : 121-32. (Pubitemid 351262491)
29. Hung RJ, Christiani DC, Risch A, et al. International Lung Cancer Consortium: pooled analysis of sequence variants in DNA repair and cell cycle pathways. Cancer Epidemiol Biomarkers Prev 2008 ; 17 : 3081-9.
30. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006 ; 355 : 983-91. (Pubitemid 44343542)
31. Rosell R, Perez-Roca L, Sanchez JJ, et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One 2009 ; 4 : e5133.
32. Cooper WA, Kohonen-Corish MR, Chan C, et al. Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions. Histopathology 2008 ; 52 : 613-22. (Pubitemid 351442671)
33. Vilmar AC, Santoni-Rugiu E, Sørensen JB. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol 2010 ; 9 : 1817-24.
34. Tseng RC, Hsieh FJ, Hsu HS,Wang YC. Minimal deletion regions in lung squamous cell carcinoma: association with abnormality of the DNA double-strand break repair genes and their applications on gene identification and prognostic biomarkers. Lung Cancer 2008 ; 59 : 332-9.
35. Vageli D, Daniil Z, Dahabreh J, et al. Phenotypic mismatch repair hMSH2 and hMLH1 gene expression profiles in primary non-small cell lung carcinomas. Lung Cancer 2009 ; 64 : 282-8.
36. Kouso H, Yoshino I, Miura N, et al. Expression of mismatch repair proteins, hMLH1/hMSH2, in non-small cell lung cancer tissues and its clinical significance. J Surg Oncol 2008 ; 98 : 377-83.
37. Gazdar AF. DNA repair and survival in lung cancer - the two faces of Janus. N Engl J Med 2007 ; 356 : 771-3. (Pubitemid 46294609)
38. Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004 ; 10 : 4939-43. (Pubitemid 39099767)
39. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011 ; 364 : 205-14.
40. Farmer H, McCabe, N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005 ; 434 : 917-21. (Pubitemid 40559006)
41. Guggenheim ER, Ondrus AE, Movassaghi M, Lippard SJ. Poly(ADP-ribose) polymerase-1 activity facilitates the dissociation of nuclear proteins from platinum-modified DNA. Bioorg Med Chem 2008 ; 16 : 10121-8.
42. Bartolucci R, Wei J, Sanchez JJ, et al. XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. Clin Lung Cancer 2009 ; 10 : 47-52.
43. Simbulan-Rosenthal CM, Haddad BR, Rosenthal DS, et al. Chromosomal aberrations in PARP(-/-) mice: genome stabilization in immortalized cells by reintroduction of poly(ADP-ribose) polymerase cDNA. Proc Natl Acad Sci U S A 1999 ; 96 : 13191-6.
44. Liu X, Luo X, Shi Y, et al. Poly (ADP-ribose) polymerase activity regulates apoptosis in HeLa cells after alkylating DNA damage. Cancer Biol Ther 2008 ; 7 : 934-41.
45. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009 ; 361 : 123-34.
46. Yan QW, Reed E, Zhong XS, et al. MZF1 possesses a repressively regulatory function in ERCC1 expression. Biochem Pharmacol 2006 ; 71 : 761-71. (Pubitemid 43208832)
47. Andrieux LO, Fautrel A, Bessard A, et al. GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells. Cancer Res 2007 ; 67 : 2114-23. (Pubitemid 46424230)
48. Bozec A, Formento P, Lassalle S, Lippens C, Hofman P, Milano G. Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts. Br J Cancer 2007 ; 97 : 65-72. (Pubitemid 47012080)